|Day Low/High||164.90 / 171.90|
|52 Wk Low/High||78.41 / 226.97|
What stocks do from here will, beyond electoral risk and potential stimulus, rely upon fourth quarter guidance.
Invest either because of their profitable portfolio, their impressive pipeline, or their technical set-up.
Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.
The short-term story for financial markets has been all about fiscal policy. This remains true.
The stock market is out of sync with the current economy, but it can be a forecasting machine. Let's see what it says.
Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.
From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.
These stocks are down some 20% over the last 30 months and look ripe for a rise.
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
I'm content to head into the weekend with my short-term book mostly on the cash side.